Summary of incidence of E-lesions by stage
| Stage . | n (E/total) . | Percentage . | Range (%) . |
|---|---|---|---|
| I | 4/365 | 1.1 | 0-6 |
| IA | 0/258 | 0 | 0-0 |
| IB | 0/32 | 0 | 0-0 |
| II | 560/2646 | 21.2 | 0-53 |
| IIA | 252/1618 | 15.6 | 3-28 |
| IIB | 284/877 | 32.4 | 0-53 |
| III | 192/877 | 21.9 | 4-33 |
| IIIA | 79/420 | 18.8 | 4-33 |
| IIIB | 90/346 | 26.0 | 21-27 |
| Stage . | n (E/total) . | Percentage . | Range (%) . |
|---|---|---|---|
| I | 4/365 | 1.1 | 0-6 |
| IA | 0/258 | 0 | 0-0 |
| IB | 0/32 | 0 | 0-0 |
| II | 560/2646 | 21.2 | 0-53 |
| IIA | 252/1618 | 15.6 | 3-28 |
| IIB | 284/877 | 32.4 | 0-53 |
| III | 192/877 | 21.9 | 4-33 |
| IIIA | 79/420 | 18.8 | 4-33 |
| IIIB | 90/346 | 26.0 | 21-27 |
| When high risk–based studies were excluded: . | |||
|---|---|---|---|
| Stage . | n (E/total) . | Percentage . | Range (%) . |
| I | 4/313 | 1.3 | 0-6 |
| IA | 0/219 | 0 | 0-0 |
| IB | 0/19 | 0 | 0-0 |
| II | 529/2437 | 21.7 | 4-53 |
| IIA | 241/1493 | 16.1 | 4-27 |
| IIB | 279/852 | 32.7 | 11-53 |
| III | 189/839 | 22.5 | 4-33 |
| IIIA | 76/382 | 19.9 | 4-33 |
| IIIB | 90/346 | 26.0 | 21-27 |
| When high risk–based studies were excluded: . | |||
|---|---|---|---|
| Stage . | n (E/total) . | Percentage . | Range (%) . |
| I | 4/313 | 1.3 | 0-6 |
| IA | 0/219 | 0 | 0-0 |
| IB | 0/19 | 0 | 0-0 |
| II | 529/2437 | 21.7 | 4-53 |
| IIA | 241/1493 | 16.1 | 4-27 |
| IIB | 279/852 | 32.7 | 11-53 |
| III | 189/839 | 22.5 | 4-33 |
| IIIA | 76/382 | 19.9 | 4-33 |
| IIIB | 90/346 | 26.0 | 21-27 |
Italicized results are subclassification-specific data. The bolded results also include data that did not specify the absence or presence of B symptoms. Studies using elevated risk–based criteria for inclusion are denoted with “§” in Table 3 or “∗” in Table 5.